Browse: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 3 |
Astrazeneca R&d Boston patentsThe following is a sampling of recent Astrazeneca R&d Boston patent applications (USPTO Patent Application #, Patent Title) sorted by month.
July 2009 - Astrazeneca R&d Boston patents
20090170849 - Quinazolinone derivatives having b-raf inhibitory activity June 2009 - Astrazeneca R&d Boston patents
20090163524 - Novel protein kinase b inhibitors - 060 20090163524 - Novel protein kinase b inhibitors - 060 20090163525 - Substituted quinazolines with anti-cancer activity 20090163525 - Substituted quinazolines with anti-cancer activity 20090149484 - Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them May 2009 - Astrazeneca R&d Boston patents
20090137601 - L-phenylalanine derivatives 20090137624 - Chemical compounds 20090131444 - Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity 20090131463 - Novel compounds 20090123474 - Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer 20090123476 - Targeted binding agents directed to upar and uses thereof 20090123478 - Human antibody molecules for il-13 20090118220 - Substituted adenines and the uses thereof 20090118261 - Quinazolinone derivatives and their use as b-raf inhibitors 20090118305 - Pyridine and pyrazine derivatives - 083 April 2009 - Astrazeneca R&d Boston patents
20090111828 - L-alanine derivatives 20090111860 - Sulfonamide compounds useful as adg receptor modulators 20090105324 - Imidazole derivatives for use as edg-1 antagonists 20090105324 - Imidazole derivatives for use as edg-1 antagonists 20090105324 - Imidazole derivatives for use as edg-1 antagonists 20090099174 - Combination 059 20090099203 - Composition 064 20090099210 - Enantiomers of selected fused heterocyclics and uses thereof March 2009 - Astrazeneca R&d Boston patents
20090060919 - Binding members for ige molecules 20090062246 - Therapeutic treatment-014 20090062267 - L-alanine derivatives as a5beta1 antagonists February 2009 - Astrazeneca R&d Boston patents
20090054394 - Polymorphisms in mgst3 are associated with elevated alat levels after ximelagatran treatment 20090054396 - Substituted thiophenes and uses thereof 20090054398 - Chemical compounds 20090054411 - 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors 20090054428 - Novel pyrimidine derivatives 965 20090054469 - Quinazolinone derivatives and their use as b-raf inhibitors 20090048203 - Substituted adenines and the uses thereof 20090048269 - Chemical compounds-821 20090036424 - Association between hla-drbi*07 allele and susceptibily to increased levels of alat following ximelagatran administration January 2009 - Astrazeneca R&d Boston patents
20090029367 - Polymorphisms in pon1 are associated with elevated alanine aminotransferase levels after ximelagatran or tacrine administration 20090029991 - Benzamide derivatives useful as histone deacetylase inhibitors 20090023719 - Pyrimidine derivatives 934 20090012084 - 3-cinnolinecarboxamide derivatives and their use for treating cancer October 2008 - Astrazeneca R&d Boston patents
20080261240 - Method 20080262811 - Crystal structure of haemophilus influenzae nad dependent dna ligase and uses thereof 20080255105 - Biphenyl derivatives and their use in treating hepatitis c 20080255183 - N-[heteroarylcarbonyl]-3-thienyl-l-alanine derivatives as a5beta1 antagonists 20080248048 - Interleukin-13 antibody composition 20080248077 - Formulation 20080242663 - Novel pyrimidine derivatives 698 September 2008 - Astrazeneca R&d Boston patents
20080221124 - Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4-[1, 3, 4-oxadiazole-2-yl] phenyl) pyridine-3-sulphonamide August 2008 - Astrazeneca R&d Boston patents
20080206303 - Prolonged release formulations comprising anastrozole 20080207616 - Quinoxalines as b baf inhhibitors 20080199481 - Compounds 20080200649 - Method 20080194552 - Aminopyrimidine derivatives with tie2 inhibiting activity 20080194556 - Quinazolines and their use as aurora kinase inhibitors 20080194606 - Pyrazolyl-amino-substituted pyrimidines and their use in the treatment of cancer July 2008 - Astrazeneca R&d Boston patents
20080182842 - L-alanine derivatives as a5beta1 antagonists 20080175834 - Carboxypertidase u (cpu) mutants 20080176872 - Chemical compounds 20080171742 - 4-(pyrid-2-yl) amino substituted pyrimidine as protein kinase inhibitors 20080167297 - Pyrimidine derivatives for use as anticancer agents 20080161278 - 2-azetidinyl-4-(1h-pyrazol-3-ylamino) pyrimidines as inhibitors of insulin-like growth factor-1 receptor activity 20080161306 - Pyrrole derivatives as dna gyrase and topoisomerase inhibitors 20080161330 - Pyrimidines as igf-i inhibitors 20080161404 - Bicalutamide for delivering increasing steady state plasma levels 20080161565 - Chemical process June 2008 - Astrazeneca R&d Boston patents
20080153799 - Novel quinoline-carbaxamides as jak3 kinase modulators 20080153812 - Novel compounds 20080153838 - Compounds having tie2 (tek) activity 20080153854 - Novel fused heterocycles and uses thereof 20080145358 - Method for determining responsiveness to chk1 inhibitors 20080145840 - Isothermal titration calorimetry assays 20080146570 - Chemical compounds 20080146599 - Pyrimidine compounds having tie-2 (tek) inhibitory activity 20080139561 - Pyrazolylaminopyridine derivatives useful as kinases inhibitors 20080132546 - Chemical compounds May 2008 - Astrazeneca R&d Boston patents
20080119451 - Novel benzamide derivatives 20080108608 - Pyrimidines with tie2 (tek) activity March 2008 - Astrazeneca R&d Boston patents
20080076780 - Combination of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent 20080064691 - Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity February 2008 - Astrazeneca R&d Boston patents
20080045481 - Novel co-crystal 20080045517 - 6h-thieno[2,3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (gnrh) 20080045521 - Phenylalanine derivatives January 2008 - Astrazeneca R&d Boston patents
20080027076 - Pyrimidines with tie2 (tek) activity 20080020416 - Enzyme and preparation method 20080021012 - 3-[4-{6-substituted alkanoyl pyridin-3-yl}-3-phenyl]-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents 20080009482 - Novel compounds 20080009512 - Tetrahydroquinolones and aza-analogues thereof for use as dpp-iv inhibitors in the treatment of diabetes 20080004302 - Novel compounds December 2007 - Astrazeneca R&d Boston patents
20070298413 - Topoisomerase modulators assays 20070287703 - Fused pyrimidones useful in the treatment and the prevention of cancer 20070281916 - Substituted isoxazolines and their use as antibacterial agents November 2007 - Astrazeneca R&d Boston patents
20070275954 - Novel fused heterocycles and uses thereof 20070275982 - Method 20070270384 - Process and intermediate 20070259849 - Azine-carboxamides as anti-cancer agents October 2007 - Astrazeneca R&d Boston patents
20070249636 - Selected fused heterocyclics and uses thereof August 2007 - Astrazeneca R&d Boston patents
20070202548 - Screening assay to identify inhibitors of the murd enzyme using an activator-independent murd enzyme 20070185106 - Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists 20070185185 - Derivatives of thienopyrrole as gnrh antagonists July 2007 - Astrazeneca R&d Boston patents
20070172425 - Testing cell cycle regulation effect of a compound using a hollow fibre cell implant 20070167428 - Thienopyrroles as antagonists of gnrh June 2007 - Astrazeneca R&d Boston patents
20070149560 - Novel fused triazolones and the uses thereof 20070142413 - Pyrazole derivatives as inhibitors of receptor tyrosone kinases 20070135455 - Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 May 2007 - Astrazeneca R&d Boston patents
20070123528 - Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity 20070117138 - Splice variant cannabinoid receptor (cb1b) April 2007 - Astrazeneca R&d Boston patents
20070092879 - Fluoresence-based dna primase assays February 2007 - Astrazeneca R&d Boston patents
20070043069 - Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase 20070037888 - 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer January 2007 - Astrazeneca R&d Boston patents
20070010556 - Thiophene derivatives as chk 1 inhibitors December 2006 - Astrazeneca R&d Boston patents
20060287241 - Combination comprising n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate 20060287379 - Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer 20060281666 - Substitute thiophenes and uses therof November 2006 - Astrazeneca R&d Boston patents
20060270637 - Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents 20060270689 - Novel fused heterocycles and uses thereof 20060270692 - Chemical compounds 20060263298 - Assay 20060264494 - Heterocyclic amide derivatives which process glycogen phorylase inhibitory activity 20060258710 - Indolylalkylamino-methylidenecarbamate derivatives useful as gnrh antagonists 20060252781 - Fused heterocycles as inhibitors of glutamate racemase(muri) October 2006 - Astrazeneca R&d Boston patents
20060235067 - 6h-thieno[2,3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (gnrh) 20060223801 - Pyrrol derivatives with antibacterial activity September 2006 - Astrazeneca R&d Boston patents
20060216774 - Method 20060211760 - Indolamide derivatives which possess glycogen phosphorylase inhibitory activity 20060199966 - Indol-2-amides as glycogen phosphorylase inhibitors
###
This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Astrazeneca R&d Boston in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Astrazeneca R&d Boston with additional patents listed. Browse our Agent directory for other possible listings.
###
FreshPatents.com Support
|